136871-75-5

Usage

Uses

Used in Pharmaceutical Synthesis:
3-Piperidinamine, 2-phenyl-, (2S,3S)is used as a key intermediate in the production of various drugs and research compounds. Its unique stereochemistry and reactivity make it an ideal candidate for the synthesis of complex organic molecules, contributing to the development of novel therapeutic agents.
Used in Medicinal Chemistry Research:
3-Piperidinamine, 2-phenyl-, (2S,3S)is utilized in medicinal chemistry research to explore its potential pharmacological activities and biological effects. Its chiral nature and reactivity allow researchers to investigate its interactions with biological targets, paving the way for the discovery of new drugs with improved efficacy and selectivity.
Used in Drug Discovery:
3-Piperidinamine, 2-phenyl-, (2S,3S)is employed in drug discovery processes to identify and optimize lead compounds with therapeutic potential. Its unique properties enable the design and synthesis of novel drug candidates, accelerating the development of innovative treatments for various diseases and conditions.

Upstream product

• 134896-35-8 2-phenyl-3-nitropyridine 
• 1294517-76-2 N-benzyl-2-phenylpyridin-3-amine 
• 1415550-83-2 (2S,3S)-benzyl 3-(benzyloxycarbonylamino)-2-phenylpiperidine-1-carboxylate 
• 32634-68-7 (2S,3S)-di-4-toluoyltartaric acid 
• 872726-33-5 (+)(2S,3S)-3-(2-methoxylbenzylamino)-2-phenylpiperidine hydrochloride 
• 168267-14-9 [2S]-phenyl-piperidin-[3S]-yl-amine [2R,3R]-bis(4-methyl-benzyloxy)-succinate 
• 98-80-6 phenylboronic acid 
• 136982-36-0 (2S,3S)-3-(2-methoxybenzylamino)-2-phenylpiperidine 

Downstream Products

• 7035-09-8 5-chloro-2-methoxybenzaldehyde 
• 168398-02-5 (+/-)-GR 203040 
• 182822-62-4 (2S,3S)-3-[2-methoxy-5-(N-methyl-N-methanesulfonylamino)-benzyl]amino-2-phenylpiperidine 

Relevant academic research and scientific papers

Synthesis and structure-activity relationships of CP-122,721, a second-generation NK-1 receptor antagonist

The synthesis and SAR of benzylamine side chain analogs of the NK-1 receptor antagonist CP-99,994 are described. The 5-trifluoromethoxy analog, CP-122,721, shows superior in vivo blockade of NK-1 receptor mediated responses.

Asymmetric Synthesis of CP-99,994 by Ring-expanding Amination of Monosubstituted Prolinols

A stereospecific synthesis of the biologically active compound (+)-CP-99,994 was achieved. The key step in this process was a ring-expansion rearrangement, in which threo-fused monosubstituted prolinol was effectively transformed to 2,3- disubstituted pip

Asymmetric Hydrogenation of 3-Amido-2-arylpyridinium Salts by Triply Chloride-Bridged Dinuclear Iridium Complexes Bearing Enantiopure Diphosphine Ligands: Synthesis of Neurokinin-1 Receptor Antagonist Derivatives

We describe a most straightforward synthetic method for preparing neurokinin-1 (NK1) receptor antagonist derivatives by asymmetric hydrogenation of 3-amido-2-arylpyridinium salts using dinuclear iridium complexes with enantiopure diphosphine ligands, affo

Stereoselective approach to cis -2,3-disubstituted piperidines via reduction of N -acyliminium ion intermediate: Enantioselective synthesis of (+)-(2 S,3 S)-CP-99,994

A very simple and efficient stereoselective approach to cis-2,3-disubstituted piperidines via the reduction of N-acyliminium ion intermediates is described. Application of this methodology is exemplified by the enantioselective total synthesis of (+)-(2S,3S)-CP-99,994.

PHARMACEUTICAL COMPOSITIONS COMPRISING 2-METHOXY-5- (5-TRIFLUOROMETHYL-TETRAZOL-I-YL-BENZYL) - (2S-PHENYL-PIPERIDIN-3S-YL-)

The present invention relates to pharmaceutical compositions comprising the NK1 receptor antagonist [2-Methoxy-5-(5-trifuoromethyl-tetrazol-1-yl)-benzyl]-(2S-phenyl- piperidin-3S-yl)-amine, or a pharmaceutically acceptable salt or solvate thereof, and a sodium channel blocker, as a combined preparation for simultaneous or sequential administration and to the use of such compositions in the treatment of certain disorders, including epilepsy, mood disorders and pain.

RADIOLABELED NEUROKININ-1 RECEPTOR ANTAGONISTS

The present invention is directed to radiolabeled neurokinin-1 receptor antagonists which are useful for the labeling and diagnostic imaging of neurokinin-1 receptors in mammals.

Method for producing optical-active cis-piperidine derivatives

An optical-active cis-piperidine derivative of high chemical purity and high optical purity is efficiently produced through optical resolution of a cis-piperidine derivative mixture, racemic cis-piperidine derivative with an optical-active tartaric acid d

Pharmaceutical agents for the treatment of emesis

The present invention relates to a novel process for preparing and resolving 3-amino-2-phenylpiperidine and for synthesizing from the enantiomers of such compound certain pharmaceutically active substituted 2-phenyl-3-benzylaminopiperidines. The substitut

F-18 radiolabeled neurokinin-1 receptor antagonists

The present invention is directed to radiolabeled neurokinin-1 receptor antagonists which are useful for the labeling and diagnostic imaging of neurokinin-1 receptors in mammals.

Substituted benzylamino nitrogen containing non-aromatic heterocycles

The present invention relates to novel substituted benzylamino nitrogen containing non-aromatic heterocycles and, specifically, to compounds of the formula STR1 wherein W, R1, R2, R3 and A are as defined in the specification, and to intermediates used in the synthesis of such compounds. The novel compounds of formula I are useful in the treatment of inflammatory and central nervous system disorders, as well as other disorders.